Antibody-drug Conjugate Information

General Information of This Antibody-drug Conjugate (ADC)
ADC ID
DRG0HHTKX
ADC Name
CD33 PNU ADC4-2
Synonyms
CD33-PNU-ADC4-2
   Click to Show/Hide
Organization
Genentech, Inc.
Drug Status
Investigative
Drug-to-Antibody Ratio
3-4
Structure
Antibody Name
Anti-CD33 mAb 15G15.33
  Antibody Info 
Antigen Name
Myeloid cell surface antigen CD33 (CD33)
  Antigen Info 
Payload Name
Undisclosed
Therapeutic Target
Stimulator of interferon genes protein (STING1)
  Target Info 
Linker Name
CD33 PNU ADC4-2 linker
General Information of The Activity Data Related to This ADC
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Standard Type Value Units Cell Line Disease Model
Half Maximal Inhibitory Concentration (IC50) 
0.6
ng/mL
EoL-1 cells
Chronic eosinophilic leukemia
Full List of Activity Data of This Antibody-drug Conjugate
Revealed Based on the Cell Line Data
Click To Hide/Show 1 Activity Data Related to This Level
Experiment 1 Reporting the Activity Date of This ADC [1]
Efficacy Data Half Maximal Inhibitory Concentration (IC50) 0.6 ng/mL Positive CD33 expression (CD33+++/++)
Method Description
The cells, at a predeterminedconcentration, were plated into 96 well plates, and, after overnight incubation at 37°C/5CO2, serialdilutions of each test article (TA) were added to the cells. Cells were incubated with test articlesfor 72 hours, and viability was detected with CellTiter-Glo reagent.
In Vitro Model Chronic eosinophilic leukemia EoL-1 cells CVCL_0258
References
Ref 1 Peptidomimetic compounds and antibody-drug conjugates thereof; 2015-09-03.